Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
TB

TYLER BEAVER

Registered · LDAActive

At a glance

Works on
Professional highlights appear here once this profile is claimed. Claim it →

Background

Career
Alexandria, VA · current

The past 12 months

Clients
2
past 12 months
Filings
3
past 12 months
Agencies contacted
Health & Human Services, Dept of (HHS)Transportation, Dept of (DOT)

Specific issues

Legislation, policies, appropriations, and regulatory relief to support the development, construction, and operation of new U.S.-based active pharmaceutical ingredient (API) manufacturing facilities; initiatives to strengthen domestic API supply chains and reduce reliance on foreign-sourced APIs; FDA regulatory streamlining and expedited review for new API manufacturing plants; federal grant, tax incentive, and contracting mechanisms to increase private investment in domestic API production; implementation of Executive Order(s) or federal policy aimed at boosting U.S.-based pharmaceutical manufacturing; relevant provisions of H.R. 1405 (Enhancing Domestic Drug Manufacturing Act), S. 257 (Promoting Resilient Supply Chains Act of 2025), the RAPID Reserve Act, and other pending bills and actions to advance U.S. pharmaceutical supply chain resilience and capacity.
Manufacturing · 2025 Q3
Discussion of proposed FAA Part 108 regulations for Beyond Visual Line of Sight (BVLOS) drone operations, including general regulatory direction, implementation approach, and potential industry impact on commercial drone operations.
Transportation · 2025 Q3
BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.
Budget/Appropriations · 2025 Q3
Advocacy for federal and state funding, grants, and pilot programs supporting drone-based logistics, emergency response, and medical delivery. Engagement on FAA and DOT UAS policy and regulatory reform, including airworthiness, Remote ID, BVLOS operations, and integration into the National Airspace System. Support for DoD, DHS, and DIU procurement and adoption of U.S.-manufactured drones for logistics and defense. Monitoring export controls, NDAA 848, ITAR, and Buy American requirements. Promotion of drone solutions for water management, infrastructure, and climate resilience. Support for advanced manufacturing and workforce development incentives.
Defense · 2025 Q2

Clients

2025 · 2 filings
$██,███ / qtrFree in beta
2025 · 3 filings
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings3
2025 Q3
SENTINEL API GROUP, INC.
Q3lda.gov →
2025 Q3
DARKFLITE, INC.
Q3lda.gov →
2025 Q3
SENTINEL API GROUP, INC.
RRlda.gov →
Older filings2
2025 Q2
DARKFLITE, INC.
Q2lda.gov →
2025 Q2
DARKFLITE, INC.
RRlda.gov →